Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma

Torben Plesner, Hendrik-Tobias Arkenau, Henk M Lokhorst, Peter Gimsing, Jakub Krejcik, Charlotte Rose Lemech, Monique Minnema, Ulrik Niels Lassen, Tahamtan Ahmadi, Howard Yeh, Mary Guckert, Nikolai C. Brun, Steen Lisby, Linda Basse, Antonio Palumbo, Paul G Richardson

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftFormidling

Abstrakt

8533
OriginalsprogEngelsk
Artikelnummer8533
TidsskriftJournal of Clinical Oncology
Vol/bind32
Udgave nummer15
ISSN0732-183X
DOI
StatusUdgivet - 2014
BegivenhedASCO 2014: Annual Meeting - Chicago, USA
Varighed: 30. maj 20143. jun. 2015

Konference

KonferenceASCO 2014
LandUSA
ByChicago
Periode30/05/201403/06/2015

Citationsformater

Plesner, T., Arkenau, H-T., Lokhorst, H. M., Gimsing, P., Krejcik, J., Rose Lemech, C., Minnema, M., Lassen, U. N., Ahmadi, T., Yeh, H., Guckert, M., C. Brun, N., Lisby, S., Basse, L., Palumbo, A., & Richardson, P. G. (2014). Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Journal of Clinical Oncology, 32(15), [8533]. https://doi.org/10.1200/jco.2014.32.15_suppl.8533